Peptide-Based HIV Vaccines: The Search So Far

Peptide HIV Vaccines

95% response rate

The HVTN 133 trial achieved a 95% serum antibody response rate using a gp41 MPER peptide-liposome immunogen, with induced antibodies neutralizing 15% of global HIV strains.

Erdmann et al., medRxiv, 2025

Erdmann et al., medRxiv, 2025

View as image

HIV has defeated every vaccine approach attempted over the past four decades. The virus mutates rapidly, cloaks its vulnerable surface proteins under a dense glycan shield, and targets the very immune cells (CD4+ T cells) needed to mount an antibody response. Despite these obstacles, peptide-based vaccine strategies have achieved results in the past five years that would have seemed unlikely a decade ago. The HVTN 133 clinical trial used a gp41 MPER peptide-liposome immunogen to elicit neutralizing antibody lineages in human volunteers, achieving a 95% serum binding antibody response rate and inducing antibodies that neutralized 15% of global tier 2 HIV strains.^[1] Epitope-focused designs using fusion peptide scaffolds have induced cross-clade neutralizing responses in animals. Computational methods can now transplant HIV epitopes onto stable protein scaffolds to present them in their native conformation. This article covers the full landscape of peptide approaches to HIV vaccination: which viral targets they pursue, what clinical and preclinical evidence exists, why the problem remains unsolved, and what recent advances suggest about the path forward. For focused coverage of HIV peptide therapeutics, see our articles on how peptides block HIV entry, the T-20 peptide story, and cyclotides and HIV.

Why HIV Vaccine Development Has Failed

The challenge of creating an HIV vaccine is fundamentally different from other vaccine targets. Most successful vaccines work by presenting the immune system with a viral protein and allowing it to generate antibodies that will recognize and neutralize the virus upon future exposure. HIV defeats this approach through several mechanisms that interact synergistically.

Antigenic diversity. HIV-1 circulates as multiple subtypes (clades A through K, plus recombinant forms) with up to 35% sequence variation in the envelope protein between clades. Even within a single infected individual, the virus exists as a swarm of quasi-species that evolve continuously. A vaccine must elicit antibodies that recognize not one viral sequence but the full spectrum of circulating variants.

Glycan shielding. The HIV envelope trimer (gp120/gp41) is covered by a dense canopy of host-derived glycans (sugar molecules) that mask protein epitopes from antibody recognition. This "glycan shield" makes the protein surface look like self to the immune system, suppressing B cell responses to the most important neutralization targets.

Immunodominant decoy epitopes. The exposed, accessible regions of gp120 are hypervariable loops that elicit strong antibody responses but are useless for protection because they differ between strains. The conserved epitopes that broadly neutralizing antibodies (bnAbs) target are structurally occluded, poorly immunogenic, and often require unusual antibody features (long CDRH3 loops, polyreactivity) that the immune system normally suppresses.

CD4+ T cell destruction. HIV preferentially infects and kills the CD4+ T helper cells required to support B cell maturation, class switching, and somatic hypermutation, the very processes needed to generate potent neutralizing antibodies.

These challenges explain why peptide approaches have attracted sustained interest: if the virus hides its vulnerable epitopes behind glycans and decoy regions, perhaps directly presenting those epitopes as isolated peptides, stripped from the full envelope protein, could focus the immune response where it matters.

The Four Major Peptide Epitope Targets

Broadly neutralizing antibodies isolated from HIV-infected individuals have identified four major conserved regions on the envelope trimer where peptide-based vaccine design concentrates.

MPER (Membrane-Proximal External Region)

The MPER is a 24-amino-acid stretch at the base of gp41, adjacent to the viral membrane. It is the target of bnAbs 2F5, 4E10, and 10E8, some of the most potent HIV-neutralizing antibodies ever isolated. The MPER is highly conserved because it is essential for membrane fusion, the final step of viral entry.

The HVTN 133 trial represents the most advanced clinical testing of a peptide-based HIV vaccine. Using MPER peptides embedded in liposomes, the immunogen induced polyclonal HIV-1 B cell lineages producing mature bnAbs and their precursors. The most potent antibodies neutralized 15% of global tier 2 HIV strains and 35% of clade B strains. The trial achieved a 95% serum binding antibody response rate and 100% peripheral blood CD4+ T cell response rate after two immunizations.^[1]

The MPER presents a specific challenge: 4E10-like antibodies that target this region are naturally produced in only about 5% of HIV-infected individuals with broadly neutralizing activity, suggesting the epitope is poorly immunogenic even during natural infection. Previous attempts to elicit MPER antibodies using soluble trimeric gp140, VLP-membrane-anchored gp41, and chimeric constructs all failed, making the HVTN 133 success a genuine breakthrough in the field.^[2]

Fusion Peptide

The N-terminal fusion peptide of gp41 is a short, hydrophobic sequence that inserts into the target cell membrane during viral entry. It is essential for infection and highly conserved across HIV clades. Xu and colleagues at the NIH Vaccine Research Center showed in 2018 that immunization with fusion peptide-carrier protein conjugates, followed by boosting with prefusion-stabilized envelope trimers, induced cross-clade neutralizing responses in animals. Epitope-scaffold immunogens presenting the fusion peptide elicited antibodies neutralizing up to 31% of a cross-clade panel of 208 HIV-1 strains.^[3]

The fusion peptide is the target of the approved drug enfuvirtide (T-20/Fuzeon), a 36-amino-acid synthetic peptide that blocks gp41-mediated virus-cell fusion. Kilby and colleagues demonstrated in 1998 that T-20 produced potent suppression of HIV-1 replication in humans, validating gp41 as a therapeutic and vaccine target.^[4] The fusion peptide's dual role as both treatment target and vaccine epitope makes it one of the most studied peptide sequences in HIV research. For the full enfuvirtide story, see enfuvirtide (Fuzeon): the HIV peptide drug that blocks viral fusion.

V3 Loop and CD4 Binding Site

The V3 loop on gp120 was the earliest peptide vaccine target attempted. It is accessible on the viral surface and elicits strong antibody responses. The problem: V3 is hypervariable between strains, so antibodies generated against one V3 sequence rarely neutralize viruses with different V3 sequences. Early peptide vaccine trials using V3 peptides generated strain-specific responses that failed to protect against diverse circulating strains.

The CD4 binding site (CD4bs) on gp120 is the most conserved functional epitope because every HIV strain must bind CD4 to infect cells. BnAbs targeting the CD4bs (like VRC01) are among the most broadly active ever isolated. Designing peptide immunogens that present the CD4bs in its native conformation is extremely challenging because the site is a conformational epitope formed by discontinuous protein segments, not a linear peptide sequence.

Scaffold-Based Approaches

The central innovation in modern peptide HIV vaccine design is computational epitope scaffolding: transplanting a short peptide epitope from its native context on the HIV envelope onto a stable, immunogenic carrier protein that presents the epitope in its correct three-dimensional conformation.

Correia and colleagues developed a computational method to design epitope-scaffolds for HIV vaccine candidates. The approach takes the crystal structure of a known bnAb-epitope complex, identifies the minimal structural epitope, searches protein structure databases for scaffold proteins with compatible backbone geometries, and grafts the epitope onto the scaffold. The resulting chimeric protein presents the HIV epitope in a stable, highly immunogenic context stripped of the distracting decoy epitopes present on the full envelope protein.

This approach addresses a fundamental limitation of linear peptide vaccines: short peptides in solution adopt random conformations and rarely match the three-dimensional shape they have on the intact protein. bnAbs recognize shape, not just sequence, so a floppy peptide generates antibodies to the wrong conformation. Scaffolding constrains the epitope in its bnAb-recognized shape, increasing the probability that elicited antibodies will recognize the native virus.

The scaffold strategy has been validated for multiple HIV epitopes. For the 2F5 epitope in the MPER, scaffold proteins presenting the complete epitope in its membrane-proximal conformation elicited antibodies with improved binding to the native gp41 compared to free peptide immunization. For the CD4 binding site, computational scaffolding is particularly valuable because the epitope is conformational (formed by non-contiguous protein segments), making it inaccessible to linear peptide approaches. Scaffold proteins that recapitulate the three-dimensional surface of the CD4bs have shown improved immunogenicity in animal models, though generating bnAb-like responses from a single scaffolded epitope remains elusive. The circulin A cyclotide, a macrocyclic knotted peptide with anti-HIV activity first characterized by Daly and colleagues in 1999, illustrates how cyclic peptide structures provide the conformational stability that linear peptides lack.^[11]

Nanoparticle and Liposome Delivery

Peptide epitopes alone are poorly immunogenic because of their small size (below the threshold for efficient B cell receptor crosslinking) and rapid proteolytic degradation in vivo. Two delivery platforms have shown particular promise for peptide HIV vaccines.

Liposome Formulations

The HVTN 133 MPER peptide-liposome approach uses the fact that the MPER epitope naturally exists in a lipid membrane context on the virus. Embedding MPER peptides in liposome bilayers recapitulates this natural presentation, and the lipid component provides adjuvant activity through innate immune receptor stimulation. The success of this approach in generating bnAb precursors in humans validates liposome delivery for peptide HIV vaccines.^[1]

Nanovaccine Platforms

Dacoba and colleagues reviewed the technological challenges in developing HIV nanovaccine candidates in 2020, identifying antigen stability, controlled release kinetics, adjuvant selection, and scalable manufacturing as key bottlenecks. Nanoparticle platforms including polymeric nanoparticles, virus-like particles, and self-assembling protein nanoparticles can display multiple copies of a peptide epitope in a repetitive array that strongly activates B cells. The manufacturing challenge is ensuring consistent epitope display and particle stability across production batches.^[5]

Cell-penetrating peptides are being explored to enhance immunogenicity. Sadat and colleagues compared two cell-penetrating peptides (IMT-P8 and LDP12) for their ability to increase the immunostimulatory properties of nanoparticle-based HIV vaccines, finding that peptide-mediated delivery of antigens to antigen-presenting cells substantially improved T cell responses.^[6]

Next-Generation Peptide Approaches

Stapled Peptides

Hydrocarbon stapling, a technique that locks peptides into stable alpha-helical conformations, is being applied to HIV peptide immunogens and therapeutics. Wang and colleagues discovered in 2024 a double-stapled short peptide that acts as a long-acting HIV-1 inactivator with potential for oral delivery, a significant pharmacological advance given that all current peptide HIV drugs require injection.^[7] Stocks and colleagues characterized native and hydrocarbon-stapled enfuvirtide conformations in 2021, demonstrating that stapling preserves the active conformation while enhancing proteolytic stability.^[8]

Defensin-Based Approaches

Theta-defensins, cyclic antimicrobial peptides found in non-human primates but not humans, have intrinsic anti-HIV activity. Mosalanejad and colleagues used computational design in 2025 to optimize a theta-defensin peptide for HIV therapy, modifying the natural sequence to enhance both antiviral potency and pharmacological properties.^[9] Plant-derived cyclotides, structurally similar cyclic peptides, also show anti-HIV activity through membrane disruption mechanisms. For more on cyclotide antiviral properties, see cyclotides and HIV: plant peptides with antiviral properties and cyclotides: the ultra-stable plant peptides with drug potential.

DNA-Peptide Hybrid Vaccines

Tajvidi and colleagues reported in 2026 that a DNA vaccine construct linking HSP70 mini-chaperones to HIV peptide epitopes enhanced immune responses, combining the sustained antigen expression of DNA vaccines with the epitope precision of peptide design.^[10] This hybrid approach addresses a key limitation of pure peptide vaccines: their transient duration in vivo. DNA delivery provides continuous antigen production, while the peptide component ensures the immune response focuses on the desired epitopes.

What Peptide Entry Inhibitors Teach Us About Vaccines

The success of enfuvirtide (T-20) as an HIV therapeutic peptide provides important validation for peptide-based vaccine approaches. T-20 is a 36-amino-acid peptide derived from the HR2 region of gp41 that blocks the six-helix bundle formation required for viral fusion. Kilby and colleagues showed in 1998 that T-20 produced dose-dependent viral load reductions of up to 2 log10 copies/mL in HIV-infected patients.^[4]

What enfuvirtide demonstrates is that peptides targeting the gp41 fusion machinery can achieve therapeutically relevant interaction with the virus. If a peptide drug can bind gp41 tightly enough to block fusion, then antibodies directed at the same gp41 epitopes should, in principle, be able to achieve viral neutralization. The challenge is generating those antibodies through vaccination rather than administering the peptide directly.

Pu and colleagues reviewed the full landscape of protein- and peptide-based HIV entry inhibitors targeting gp120 and gp41 in 2019, documenting multiple peptide sequences beyond T-20 that effectively block viral entry at various stages.^[3] Each successful entry inhibitor peptide identifies another potential vaccine epitope, and next-generation fusion inhibitor peptides incorporating pan-coronavirus activity suggest these targets are conserved across related viruses. For how these mechanisms work, see how peptides block HIV entry: fusion inhibitor mechanisms. For the broader landscape of peptide antiviral approaches, see EK1: the pan-coronavirus fusion inhibitor peptide and antiviral peptides against influenza.

The structure-function relationship of the gp41 fusion peptide has been characterized in detail. Serrano and colleagues used nuclear magnetic resonance spectroscopy to reveal the conserved structural features of the HIV-1 fusion peptide sequence, demonstrating that even small mutations in this region dramatically reduce fusogenic activity.^[2] This structural conservation under functional constraint is precisely what makes the fusion peptide an attractive vaccine target: the virus cannot easily escape antibodies targeting this region without losing its ability to infect cells.

Limitations and Honest Assessment

After four decades and billions of dollars, no HIV vaccine of any type provides durable protection. Peptide approaches have made genuine advances but face specific limitations.

Narrow neutralization breadth. The best peptide vaccine result (HVTN 133 MPER peptide-liposome) neutralized 15% of global tier 2 strains. A clinically useful vaccine would need to neutralize >80% of circulating strains. Closing this gap requires either more potent single-epitope responses or multi-epitope cocktails, both of which are being pursued.

Immune tolerance mechanisms. Some bnAb-like antibodies (particularly those targeting MPER) show polyreactivity with self-antigens. The immune system actively suppresses these B cell lineages through tolerance checkpoints, meaning the very antibodies needed for protection are the ones the body tries not to make. Overcoming immune tolerance without inducing autoimmunity is an unsolved problem.

Conformational fidelity. Even with scaffolding and liposome presentation, ensuring that a peptide epitope perfectly mimics its conformation on the native envelope trimer is technically difficult. Small conformational differences between the immunogen and the viral target can generate antibodies that bind the vaccine but not the virus.

Sequential immunization complexity. The emerging strategy of "germline targeting" involves sequential immunizations with different immunogens, each designed to guide naive B cells through a specific maturation pathway toward bnAb production. This requires identifying precursor B cell lineages, designing immunogens that activate them, and then boosting with progressively more complex antigens. While scientifically elegant, this multi-step approach creates practical challenges for deployment in resource-limited settings where HIV burden is highest.

Competition from other modalities. mRNA vaccines, vectored approaches, and passive immunization with bnAb infusions are all advancing in parallel. Peptide vaccines compete for clinical trial resources and funding against these approaches, each with its own advantages.

The honest assessment is that peptide vaccines for HIV remain a research endeavor, not an imminent clinical product. The HVTN 133 results represent the first time a peptide HIV immunogen has induced bnAb lineages in humans, which is a genuine milestone. Whether this can be expanded to broad enough protection for clinical deployment is unknown.

The Bottom Line

Peptide-based HIV vaccines target conserved epitopes on gp41 (MPER, fusion peptide) and gp120 (V3, CD4 binding site) to elicit broadly neutralizing antibodies. The HVTN 133 trial achieved a 95% serum antibody response using an MPER peptide-liposome immunogen, with induced antibodies neutralizing 15% of global strains. Scaffold-based designs, stapled peptides, defensin approaches, and DNA-peptide hybrids represent next-generation strategies. Despite this progress, no peptide HIV vaccine has achieved clinical efficacy, and the gap between current neutralization breadth and the protection threshold remains large.

Frequently Asked Questions

Is there a peptide vaccine for HIV?

No peptide-based HIV vaccine has been approved or shown efficacy in a phase III trial. The most advanced candidate, an MPER peptide-liposome immunogen tested in the HVTN 133 trial, achieved a 95% serum antibody response rate and induced antibodies neutralizing 15% of global HIV strains (Erdmann et al., 2025). This represents the first successful induction of broadly neutralizing antibody lineages by a peptide HIV vaccine in humans, but the neutralization breadth is not yet sufficient for clinical protection.

What part of HIV do peptide vaccines target?

Peptide HIV vaccines primarily target four conserved regions on the viral envelope: the membrane-proximal external region (MPER) on gp41, the N-terminal fusion peptide on gp41, the V3 loop on gp120, and the CD4 binding site on gp120. These regions are conserved because they are essential for viral entry into host cells, making them less likely to mutate without fitness cost. The MPER and fusion peptide have shown the most promise because they are linear epitopes accessible to peptide mimicry.

Why is it so hard to make an HIV vaccine?

HIV evades vaccination through multiple mechanisms working simultaneously: extreme genetic diversity (up to 35% sequence variation between clades), a dense glycan shield that masks protein surfaces from antibodies, immunodominant decoy epitopes that divert the immune response to variable regions, and direct destruction of CD4+ T helper cells needed to support antibody maturation. The conserved epitopes that broadly neutralizing antibodies target are structurally hidden and poorly immunogenic, and some required antibody features are actively suppressed by immune tolerance mechanisms.

What is epitope scaffolding for HIV vaccines?

Epitope scaffolding is a computational method that transplants a short HIV peptide epitope from the viral envelope onto a stable carrier protein that presents the epitope in its correct three-dimensional shape. This addresses the problem that free peptides in solution adopt random conformations that differ from their shape on the intact virus. By constraining the epitope in its antibody-recognized conformation on a scaffold protein, the immune response is more likely to generate antibodies that recognize the actual virus.

How does enfuvirtide relate to HIV vaccines?

Enfuvirtide (T-20/Fuzeon) is a 36-amino-acid therapeutic peptide that blocks HIV entry by targeting gp41. Its clinical success, reducing viral load by up to 100-fold in treated patients (Kilby et al., Nature Medicine, 1998), validates gp41 as a target for peptide-based approaches. The same gp41 epitopes that enfuvirtide binds therapeutically are targets for vaccine-elicited antibodies. If a peptide drug can block viral fusion, antibodies directed at the same sites should be able to neutralize the virus. The challenge is generating those antibodies through vaccination.

What are the newest peptide approaches to HIV?

Three approaches represent the cutting edge as of 2026: double-stapled peptides that lock HIV-inactivating sequences into stable conformations for potential oral delivery (Wang et al., Journal of Medicinal Chemistry, 2024); computationally optimized theta-defensin peptides with enhanced antiviral potency (Mosalanejad et al., 2025); and DNA-peptide hybrid vaccines that combine sustained antigen expression with epitope-focused immune targeting (Tajvidi et al., 2026). These build on the HVTN 133 MPER peptide-liposome results showing that peptide immunogens can induce broadly neutralizing antibody precursors in humans.